Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 7OTHER 1NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Squamous Cell Carcinoma of Head and Neck 1Carcinoma, Squamous Cell 1

Interventions

Specimen Handling 123Magnetic Resonance Spectroscopy 117Cyclophosphamide 109pembrolizumab 88Radiotherapy 83Nivolumab 73Cisplatin 68fludarabine 65Biopsy 60Carboplatin 59Standard of Care 49Radiosurgery 45Gemcitabine 44Paclitaxel 42Dexamethasone 42Radiation 39Doxorubicin 39Rituximab 38Blood Specimen Collection 37Bevacizumab 37venetoclax 36Cytarabine 36Surveys and Questionnaires 35fludarabine phosphate 33Capecitabine 33Temozolomide 31Radiotherapy, Intensity-Modulated 31Practice Guidelines as Topic 31Ipilimumab 28Interviews as Topic 28

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Tiragolumab × 30 days × Clear all
NCT05681039 2026-06-02

Phase 2 Trial of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab in Patients With Newly Diagnosed PD-L1 CPS Positive Resectable Stage 3-4 Oral Cavity Squamous Cell Carcinoma (OCSCC).

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
29 enrolled
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡